Pioneering Gene Therapies for Patients in Need


Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.


We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, Reqorsa® Immunogene Therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer and small cell lung cancer.

Management Team

We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us

At Genprex, we are committed to developing life-changing gene therapies for patients afflicted with cancer and diabetes. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease. 

What they’re saying

In the Media

Catch up with our

Latest News

Genprex to Present at BIO-Europe 2023 Conference 

Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC

Genprex to Host a Virtual Key Opinion Leader Event on “Bringing Gene Therapy  to the Fight Against Lung Cancers”

Webinar to be held on Friday, October 27, 2023 from 12:30 pm – 1:45 pm Eastern Time

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®

How Strategically Partnering With Academia Supports Biotech R&D Goals

Genprex’s Chief Financial Officer, Ryan Confer, shares his insight on partnering with academic institutions, the benefits, and best practices